PYRICARBATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H15N3O4
Molecular Weight	253.2545
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC(=O)OCC1=CC=CC(COC(=O)NC)=N1

InChI

InChIKey=YEKQSSHBERGOJK-UHFFFAOYSA-N

InChI=1S/C11H15N3O4/c1-12-10(15)17-6-8-4-3-5-9(14-8)7-18-11(16)13-2/h3-5H,6-7H2,1-2H3,(H,12,15)(H,13,16)

HIDE SMILES / InChI

Molecular Formula	C11H15N3O4
Molecular Weight	253.2545
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.medoteka.ru/components/pyricarbate
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/213636

Parmidin (pyridinol carbamate) is a Soviet drug, has anti-arteriosclerotic (increased vascular resistance) activity, reduces the permeability of blood vessels, it helps to restore disturbed microcirculation in pathological processes. This is mainly due to the influence on kinin system, especially with a decrease in the activity of bradykinin receptors. It also reduces the aggregation of platelets. It’s used to treat: the brain vascular atherosclerosis, heart, limbs; diabetic retinopathy (non-inflammatory lesion of the retina associated with increased levels of sugar in the blood); thrombosis (violation of patency) retinal vein; occlusive disease (inflammation of the inner lining of arteries with a decrease in their lumen); trophic leg ulcers (slow-healing skin defects caused by malnutrition). Ointment is used in neurodermatitis (skin disease caused by disturbance of the central nervous system), Lichen sclerosus (teardrop scleroderma) genital organs of children, as well as a prophylactic and therapeutic agent against radiation skin lesions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bradykinin B1 receptor 2 Target ID: CHEMBL4308 Sources: DOI: 10.1007/BF00776332 Tugusheva, N.Z., Ershov, L.V., Granik, V.G. et al. Pharm Chem J (1986) 20: 483. doi:10.1007/BF00776332	Antagonist 2849
Bradykinin B2 receptor 3 Target ID: CHEMBL3157 Sources: DOI: 10.1007/BF00776332 Tugusheva, N.Z., Ershov, L.V., Granik, V.G. et al. Pharm Chem J (1986) 20: 483. doi:10.1007/BF00776332	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Atherosclerosis of vessels of the brain, heart, limbs, eyes 1 Sources: http://www.rlsnet.ru/tn_index_id_11562.htm	Primary	Approved 8583	Parmidin tablets 0,25 g Approved Use Atherosclerosis of vessels of the brain, heart, limbs, eyes (comprehensive treatment and prevention).
Neurodermatitis 5 Sources: http://www.piluli.kharkov.ua/drugs/drug/531/	Palliative	Approved 8583	Parmidin Approved Use Unknown
Lichen sclerosus 1 Sources: http://www.piluli.kharkov.ua/drugs/drug/531/	Palliative	Approved 8583	Parmidin Approved Use Unknown
Diabetic retinopathy 17 Sources: http://www.piluli.kharkov.ua/drugs/drug/531/	Palliative	Approved 8583	Parmidin Approved Use Unknown

C_max

Value	Dose	Analyte	Population
18.28 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6745304/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6745304/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501551/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
15.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501551/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
187.36 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6745304/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
249.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6745304/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
132.77 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501551/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
142.28 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501551/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
5.86 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6745304/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6745304/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501551/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501551/	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:	PYRICARBATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
2250 mg 1 times / day multiple, oral Highest studied dose Dose: 2250 mg, 1 times / day Route: oral Route: multiple Dose: 2250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/	Other AEs: Headache, Chest ache... Other AEs: Headache (mild, 1 pt) Chest ache (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/

AEs

AE	Significance	Dose	Population
Chest ache	1 pt	2250 mg 1 times / day multiple, oral Highest studied dose Dose: 2250 mg, 1 times / day Route: oral Route: multiple Dose: 2250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/
Headache	mild, 1 pt	2250 mg 1 times / day multiple, oral Highest studied dose Dose: 2250 mg, 1 times / day Route: oral Route: multiple Dose: 2250 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/5304316/

PubMed

Title	Date	PubMed
Effects of phthalazinol (EG 626) and pyridinolcarbamate (Anginin) on lipolytic enzyme activities in rat adipose tissue -in vivo and in vitro-.	1980-02	6249948
[Lipid synthesis in normal and atherosclerotic human intima in vitro under the effect of pyridinolcarbamate].	1976	973428

Patents

Sample Use Guides

In Vivo Use Guide

Oral: 0.25-0.75 g 3-4 times/day. The course: 2-6 months. Topical:- 2-3 times a day for 10-12 days

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:47:52 GMT 2025` Edited by `admin` on `Mon Mar 31 18:47:52 GMT 2025`
Record UNII	81R511UV73
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PYRICARBATE

Official Name

English

PYRIDINOL CARBAMATE

Preferred Name

English

COLESTERINEX

Brand Name

English

CICLOVEN

Brand Name

English

PYRICARBATE [MART.]

Common Name

English

ATEROSAN

Brand Name

English

PYRIDINOLCARBAMATE

Common Name

English

H-3749

Code

English

SOSPITAN

Brand Name

English

2,6-PYRIDINEDIMETHANOL BIS(METHYLCARBAMATE) (ESTER)

Common Name

English

PYRIDINOL CARBAMATE [JAN]

Common Name

English

2,6-PYRIDINEDIYLDIMETHYLENE BIS(METHYLCARBAMATE)

Systematic Name

English

PYRIDINOL CARBAMATE [MI]

Common Name

English

MOVECIL

Brand Name

English

VASOVERIN

Brand Name

English

2,6-PYRIDINYLENEBIS(METHYL-N-METHYLCARBAMATE)

Common Name

English

RAVENIL

Brand Name

English

ANGIOXINE

Brand Name

English

VASOCIL

Brand Name

English

ANGININ

Brand Name

English

pyricarbate [INN]

Common Name

English

DUVALINE

Brand Name

English

ATOVER

Brand Name

English

PRODECTIN

Brand Name

English

Pyricarbate [WHO-DD]

Common Name

English

VASAGIN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29703